Capricor Therapeutics (NASDAQ:CAPR) Director Sells 53,735 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $31.03, for a total transaction of $1,667,397.05. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Karimah Es Sabar also recently made the following trade(s):

• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05.

Capricor Therapeutics Price Performance

NASDAQ CAPR traded up $1.50 during trading hours on Thursday, reaching $31.62. 346,173 shares of the stock traded hands, compared to its average volume of 1,371,751. The stock has a 50 day simple moving average of $27.04 and a two-hundred day simple moving average of $18.74. Capricor Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $40.37. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -13.99 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Farther Finance Advisors LLC purchased a new position in Capricor Therapeutics in the 3rd quarter worth approximately $28,000. Parkside Financial Bank & Trust bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $36,000. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 2,786 shares during the last quarter. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter worth $43,000. Finally, GoalVest Advisory LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter worth $59,000. 21.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Maxim Group upped their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.